Department of Congenital Heart Disease and Pediatric Cardiology, Deutsches Herzzentrum München, Technische Universität München, Lazarettstr. 36, 80636 Munich, Germany.
Institute of Preventive Pediatrics, Technische Universität München, Georg-Brauchle-Ring 60/62, 80992 München, Germany.
Eur J Cardiovasc Nurs. 2024 Jan 12;23(1):55-61. doi: 10.1093/eurjcn/zvad032.
High-sensitive troponin T (hs-TnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and C-reactive protein (CRP) are established prognostic biomarkers for cardiovascular (CV) morbidity and mortality and frequently used in symptomatic and/or hospitalized adults with congenital heart disease (ACHD). Their prognostic value in clinically stable ACHD has not yet been well established. This study investigates the predictive value of hs-TnT, NT-proBNP, and CRP for survival and CV events in stable ACHD.
In this prospective cohort study, 495 outpatient ACHD (43.9 ± 10.0 years, 49.1% female) underwent venous blood sampling including hs-TnT, NT-proBNP, and CRP. Patients were followed up for survival status and the occurrence of CV events. Survival analyses were performed with Cox proportional hazards regression analysis and Kaplan-Meier curves. During a mean follow-up of 2.8 ± 1.0 years, 53 patients (10.7%) died or reached a cardiac-related endpoint including sustained ventricular tachycardia, hospitalization with cardiac decompensation, ablation, interventional catheterization, pacer implantation, or cardiac surgery. Multivariable Cox regression revealed hs-TnT (P = 0.005) and NT-proBNP (P = 0.018) as independent predictors of death or cardiac-related events in stable ACHD, whilst the prognostic value of CRP vanished after multivariable adjustment (P = 0.057). Receiver-operator characteristic curve analysis identified cut-off values for event-free survival of hs-TnT ≤9 ng/L and NT-proBNP ≤200 ng/L. Patients with both increased biomarkers had a 7.7-fold (confidence interval 3.57-16.40, P < 0.001) higher risk for death and cardiac-related events compared with patients without elevated blood values.
Subclinical values of hs-TnT and NT-proBNP are a useful, simple, and independent prognostic tool for adverse cardiac events and survival in stable outpatient ACHD.
German Clinical Trial Registry DRKS00015248.
高敏肌钙蛋白 T(hs-TnT)、氨基末端 B 型利钠肽前体(NT-proBNP)和 C 反应蛋白(CRP)是心血管(CV)发病率和死亡率的既定预后生物标志物,常用于有症状和/或住院的先天性心脏病(ACHD)成人。它们在临床稳定的 ACHD 中的预后价值尚未得到很好的确定。本研究旨在探讨 hs-TnT、NT-proBNP 和 CRP 对稳定型 ACHD 患者生存和 CV 事件的预测价值。
在这项前瞻性队列研究中,495 名门诊 ACHD 患者(43.9 ± 10.0 岁,49.1%为女性)接受了静脉血样采集,包括 hs-TnT、NT-proBNP 和 CRP。患者接受了生存状况和 CV 事件的随访。使用 Cox 比例风险回归分析和 Kaplan-Meier 曲线进行生存分析。在平均 2.8 ± 1.0 年的随访期间,53 名患者(10.7%)死亡或达到心脏相关终点,包括持续性室性心动过速、心脏失代偿住院、消融、介入导管插入术、起搏器植入或心脏手术。多变量 Cox 回归显示,hs-TnT(P = 0.005)和 NT-proBNP(P = 0.018)是稳定型 ACHD 患者死亡或心脏相关事件的独立预测因子,而 CRP 的预后价值在多变量调整后消失(P = 0.057)。受试者工作特征曲线分析确定了 hs-TnT≤9ng/L 和 NT-proBNP≤200ng/L 的无事件生存的截断值。与无升高生物标志物的患者相比,hs-TnT 和 NT-proBNP 同时升高的患者死亡和心脏相关事件的风险增加了 7.7 倍(置信区间 3.57-16.40,P<0.001)。
hs-TnT 和 NT-proBNP 的亚临床值是稳定的门诊 ACHD 患者不良心脏事件和生存的有用、简单和独立的预后工具。
德国临床试验注册处 DRKS00015248。